anti-CD19/BCMA CAR-T cells

Galapagos's lead CD19 CAR-T candidate GLPG5101 demonstrated compelling clinical results across three non-Hodgkin lymphoma indications, with complete response rates of 100% in MCL and 95% in MZL/FL.

EsoBiotec's ESO-T01, an in vivo BCMA CAR-T therapy, has dosed its first patient in a Phase 1 investigator-initiated trial in China for relapsed/refractory multiple myeloma.

GSK's Blenrep, previously withdrawn, aims for re-approval as a combination therapy for multiple myeloma after at least one prior line of treatment.